Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 8:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1297–1320 of 1,690 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Men Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Feasibility of an Oral Intervention for Sexual Health in Transgender Men

NCT06470906
View directory record Official record
Conditions
Vaginal Dysbiosis, Vaginal Disease, Molecular-bacterial Vaginosis
Interventions
Probiotic Group, Placebo Group
Dietary Supplement
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 45 Years · Male only
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated May 9, 2025 · Synced Oct 31, 2026, 8:40 PM EDT
Active, not recruiting Phase 1 Interventional

PET Imaging Study of 89Zr-DFO-YS5 in Men With Prostate Cancer

NCT05245006
View directory record Official record
Conditions
Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
Interventions
89Zr-DFO-YS5, YS5 antibody, Positron Emission Tomography (PET)/Computerized tomography (CT), Positron Emission Tomography (PET)/Magnetic Resonance Imaging (MRI)
Drug · Biological · Procedure
Lead sponsor
Robert Flavell, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 31, 2026, 8:40 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Just-In-Time Intervention to Reduce Alcohol-Facilitated Intimate Partner Violence Perpetration

NCT05145868
View directory record Official record
Conditions
Alcohol Drinking, Aggression, Emotion Regulation
Interventions
Alcohol Skills and Emotion Regulation Intervention, Attention Control
Behavioral · Other
Lead sponsor
Georgia State University
Other
Eligibility
18 Years to 30 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 31, 2026, 8:40 PM EDT
Recruiting Phase 3 Interventional

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

NCT06629779
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Cancer
Interventions
PF-06821497, Placebo, Enzalutamide
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
39
States / cities
Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Oct 31, 2026, 8:40 PM EDT
Terminated Phase 2 Interventional Results available

Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects

NCT04030559
View directory record Official record
Conditions
ATM Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation, BRIP1 Gene Mutation, CDK12 Gene Mutation, CHEK1 Gene Mutation, CHEK2 Gene Mutation, DNA Damage Response Gene Mutation, DNA Repair Gene Mutation, FANCA Gene Mutation, FANCD2 Gene Mutation, FANCL Gene Mutation, GEN1 Gene Mutation, NBN Gene Mutation, Prostate Carcinoma, RAD51 Gene Mutation, RAD51C Gene Mutation
Interventions
Niraparib, Niraparib Tosylate Monohydrate, Radical Prostatectomy
Drug · Procedure
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 31, 2026, 8:40 PM EDT
Withdrawn Early Phase 1 Interventional

A Study of Tazemetostat (Tazverik) Before Prostatectomy in Men With Prostate Cancer

NCT05567679
View directory record Official record
Conditions
Prostate Cancer
Interventions
Tazverik
Drug
Lead sponsor
Edwin Posadas, MD
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 22, 2023 · Synced Oct 31, 2026, 8:40 PM EDT
Completed No phase listed Observational

Men With Metastatic Castrate-Resistant Prostate Cancer Treated With Either Sipuleucel-T (Provenge®), Abiraterone Acetate (Zytiga®) or Enzalutamide (Xtandi®) Undergoing Cardiopulmonary EXercise Testing

NCT02353715
View directory record Official record
Conditions
Prostate Cancer
Interventions
Enzalutamide, Abiraterone acetate, Sipuleucel-T
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Male only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 24, 2020 · Synced Oct 31, 2026, 8:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Increasing MSM in the Continuum of Care in Kazakhstan

NCT02786615
View directory record Official record
Conditions
HIV, Substance-Related Disorders
Interventions
Peer Unity
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older · Male only
Enrollment
987 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 27, 2022 · Synced Oct 31, 2026, 8:40 PM EDT
Not listed Phase 2 Interventional

Open-label Extension Study of the Effects of Pomegranate Extract on Rising PSA After Primary Therapy for Prostate Cancer

NCT00731848
View directory record Official record
Conditions
Prostate Cancer
Interventions
pomegranate liquid extract
Dietary Supplement
Lead sponsor
Roll International Corporation
Industry
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 16, 2012 · Synced Oct 31, 2026, 8:40 PM EDT
Terminated Phase 2 Interventional Results available

Study of Brentuximab Vedotin And Bevacizumab In Refractory CD-30 Positive Germ Cell Tumors

NCT02988843
View directory record Official record
Conditions
Germ Cell Tumor
Interventions
Brentuximab Vedotin, Bevacizumab
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Oct 31, 2026, 8:40 PM EDT
Enrolling by invitation Phase 2 Interventional

Using Mobile Stress Management to Reduce Hypertension in African American Men

NCT07594808
View directory record Official record
Conditions
Hypertension
Interventions
mobile cognitive behavioral stress management intervention, Diploma in Stress Management course
Behavioral
Lead sponsor
ISA Associates, Inc.
Other
Eligibility
18 Years and older · Male only
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 31, 2026, 8:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Peer Intervention Latino Immigrant MSM

NCT03922126
View directory record Official record
Conditions
HIV Infections, Sexually Transmitted Diseases
Interventions
Peer counseling, HIV/STI self-testing kits
Other · Diagnostic Test
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 17, 2022 · Synced Oct 31, 2026, 8:40 PM EDT
Completed No phase listed Observational

Epidemiology of Coronary Heart Disease in Men Aged 40 and Over

NCT00069797
View directory record Official record
Conditions
Atherosclerosis, Coronary Arteriosclerosis, Coronary Disease, Heart Diseases, Cardiovascular Diseases
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
40 Years to 49 Years · Male only
Enrollment
1,027 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 15, 2013 · Synced Oct 31, 2026, 8:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Detect Radioactivity of [14C]-OPC-167832 in Urine and Feces in Healthy Men

NCT07314320
View directory record Official record
Conditions
Healthy Volunteers
Interventions
[14C]-OPC-167832
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 2, 2026 · Synced Oct 31, 2026, 8:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Intermittent Fasting, Caloric Restriction and Body Composition in Obese Men and Women

NCT02525419
View directory record Official record
Conditions
Weight Loss
Interventions
Weight Loss Phase, HP-IF, HH
Behavioral
Lead sponsor
Skidmore College
Other
Eligibility
30 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Saratoga Springs, New York
Source: ClinicalTrials.gov public record
Updated Aug 24, 2015 · Synced Oct 31, 2026, 8:40 PM EDT
Completed No phase listed Observational

A Study of the Pre- and Post-operative Semen Analyses and Reproductive Hormone Levels of Men Undergoing Weight-reduction Surgery

NCT00596739
View directory record Official record
Conditions
Male Infertility
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 17, 2016 · Synced Oct 31, 2026, 8:40 PM EDT
Completed Phase 1Phase 2 Interventional

Effects of Tomato-Soy Juice on Biomarkers in Patients With Prostate Cancer Undergoing Prostatectomy

NCT01009736
View directory record Official record
Conditions
Prostate Cancer
Interventions
tomato-soy juice, laboratory biomarker analysis, pharmacological study, therapeutic conventional surgery
Dietary Supplement · Other · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 16, 2014 · Synced Oct 31, 2026, 8:40 PM EDT
Completed Phase 1 Interventional

Effects of BufferGel and PRO 2000/5 Gel in Men

NCT00016536
View directory record Official record
Conditions
HIV Infections
Interventions
Naphthalene 2-sulfonate polymer, Carbopol polymer
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1997
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 31, 2026, 8:40 PM EDT
Completed Phase 1 Interventional Results available

Safety and Tolerability Study of MDV3100 in Combination With Docetaxel in Men With Advanced Prostate Cancer

NCT01565928
View directory record Official record
Conditions
Prostate Cancer
Interventions
MDV3100
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
3
States / cities
New York, New York • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 22, 2019 · Synced Oct 31, 2026, 8:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Physical Activity Smartphone App for African American Men (FitBros) Ph II

NCT05621044
View directory record Official record
Conditions
Exercise, Health Behavior, Technology
Interventions
FitBrothers smartphone active app, Nike Training Club
Behavioral
Lead sponsor
Klein Buendel, Inc.
Industry
Eligibility
30 Years and older · Male only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
3
States / cities
Golden, Colorado • Washington D.C., District of Columbia • Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 31, 2026, 8:40 PM EDT
Active, not recruiting Phase 2 Interventional

Hypofractionated Proton Beam Therapy for Localized Prostate Cancer

NCT01950351
View directory record Official record
Conditions
Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7
Interventions
Laboratory Biomarker Analysis, Proton Beam Radiation Therapy, Quality-of-Life Assessment
Other · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 31, 2026, 8:40 PM EDT
Completed Phase 2 Interventional Results available

A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy

NCT03043807
View directory record Official record
Conditions
Prostate Cancer
Interventions
Leuprolide Acetate, Docetaxel, Bicalutamide, Radiation, Abiraterone Acetate
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 80 Years · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Oct 31, 2026, 8:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate and Compare the PK Profiles of Abaloparatide-SC and Abaloparatide-sMTS in a Cohort of Healthy Men and Healthy Women.

NCT04663464
View directory record Official record
Conditions
Healthy Volunteers
Interventions
abaloparatide-sMTS, abaloparatide-SC
Combination Product
Lead sponsor
Radius Health, Inc.
Industry
Eligibility
40 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 6, 2022 · Synced Oct 31, 2026, 8:40 PM EDT
Completed Phase 3 Interventional Results available

Behavioral Treatment of Overactive Bladder in Men

NCT01187498
View directory record Official record
Conditions
Overactive Bladder
Interventions
Behavioral training, Oxybutynin chloride, extended-release
Behavioral · Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
19 Years and older · Male only
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
2
States / cities
Birmingham, Alabama • Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Oct 31, 2026, 8:40 PM EDT